Christopher Navara to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Christopher Navara has written about Protein-Tyrosine Kinases.
Connection Strength
0.391
-
Navara CS. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Curr Pharm Des. 2004; 10(15):1739-44.
Score: 0.218
-
Malaviya R, Navara C, Uckun FM. Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. Immunity. 2001 Aug; 15(2):313-21.
Score: 0.046
-
Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001 May; 1(1):59-71.
Score: 0.045
-
Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec; 295(3):912-26.
Score: 0.044
-
Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem. 1999 Jan 15; 274(3):1646-56.
Score: 0.039